These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33600097)

  • 1. Investigation of the relationship between immune checkpoints and mismatch repair deficiency in recurrent and nonrecurrent glioblastoma.
    Çakır E; Saygın İ; Ercin ME
    Turk J Med Sci; 2021 Aug; 51(4):1800-1808. PubMed ID: 33600097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA).
    Almuhaisen G; Alhalaseh Y; Mansour R; Abu-Shanab A; Al-Ghnimat S; Al-Hussaini M
    Brain Tumor Pathol; 2021 Jan; 38(1):14-22. PubMed ID: 32897465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.
    Hodges TR; Ott M; Xiu J; Gatalica Z; Swensen J; Zhou S; Huse JT; de Groot J; Li S; Overwijk WW; Spetzler D; Heimberger AB
    Neuro Oncol; 2017 Aug; 19(8):1047-1057. PubMed ID: 28371827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.
    Zhao P; Li L; Jiang X; Li Q
    J Hematol Oncol; 2019 May; 12(1):54. PubMed ID: 31151482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.
    Élez E; Mulet-Margalef N; Sanso M; Ruiz-Pace F; Mancuso FM; Comas R; Ros J; Argilés G; Martini G; Sanz-Garcia E; Baraibar I; Salvà F; Noguerido A; Cuadra-Urteaga JL; Fasani R; Garcia A; Jimenez J; Aguilar S; Landolfi S; Hernández-Losa J; Braña I; Nuciforo P; Dienstmann R; Tabernero J; Salazar R; Vivancos A
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.
    Salewski I; Henne J; Engster L; Schneider B; Lemcke H; Skorska A; Berlin P; Henze L; Junghanss C; Maletzki C
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
    Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
    Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
    Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
    Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
    Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY
    Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Programmed Cell Death-L1 (PD-L1) Protein and Mismatch Repair Mutations in Orbital Tumours-a Pilot Study.
    AlSemari MA; Strianese D; Abu Safieh L; Al Hussain H; Abedalthagafi M; Edward DP
    Eur J Ophthalmol; 2022 Sep; 32(5):3097-3102. PubMed ID: 34931541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
    Ji X; Sui L; Song K; Lv T; Zhao H; Yao Q
    Cancer Med; 2021 Jul; 10(14):4743-4751. PubMed ID: 34076351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological characteristics, molecular landscape, and biomarker landscape for predicting the efficacy of PD-1/PD-L1 inhibitors in Chinese population with mismatch repair deficient urothelial carcinoma: a real-world study.
    Ma YT; Hua F; Zhong XM; Xue YJ; Li J; Nie YC; Zhang XD; Ma JW; Lin CH; Zhang HZ; He W; Sha D; Zhao MQ; Yao ZG
    Front Immunol; 2023; 14():1269097. PubMed ID: 38022513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined prognostic value of CD274 (PD-L1)/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status.
    Ahtiainen M; Wirta EV; Kuopio T; Seppälä T; Rantala J; Mecklin JP; Böhm J
    Mod Pathol; 2019 Jun; 32(6):866-883. PubMed ID: 30723299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies).
    Ono R; Nakayama K; Nakamura K; Yamashita H; Ishibashi T; Ishikawa M; Minamoto T; Razia S; Ishikawa N; Otsuki Y; Nakayama S; Onuma H; Kurioka H; Kyo S
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential.
    Yang T; Kong Z; Ma W
    Hum Vaccin Immunother; 2021 Feb; 17(2):546-553. PubMed ID: 32643507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma.
    Goeppert B; Roessler S; Renner M; Singer S; Mehrabi A; Vogel MN; Pathil A; Czink E; Köhler B; Springfeld C; Pfeiffenberger J; Rupp C; Weiss KH; Schirmacher P; von Knebel Doeberitz M; Kloor M
    Br J Cancer; 2019 Jan; 120(1):109-114. PubMed ID: 30377340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of mismatch repair deficiency in sarcomas.
    Doyle LA; Nowak JA; Nathenson MJ; Thornton K; Wagner AJ; Johnson JM; Albrayak A; George S; Sholl LM
    Mod Pathol; 2019 Jul; 32(7):977-987. PubMed ID: 30765880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
    Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
    Front Immunol; 2021; 12():798424. PubMed ID: 35145511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.